Lung dendritic cells: targets for therapy in allergic disease.
Dendritic cells (DCs) are crucial in determining the functional outcome of allergen encounter in the lung. Antigen presentation by myeloid DCs leads to Th2 sensitization typical of allergic disease, whereas antigen presentation by plasmacytoid DCs serves to dampen inflammation. It is increasingly clear that DCs have an antigen presenting function beyond sensitisation. DCs therefore constitute a novel target for the development of antiallergic therapy aimed at the origin of the inflammatory cascade. A careful study of DC biology and of the receptors expressed by lung DCs has provided a framework for the discovery of novel antiallergic compounds.
Lambrecht
Bart N
BN
Department of Pulmonary Medicine, Erasmus M.C. Dr. Molerwaterplein 50, 3015 GE, Rotterdam, The Netherlands. b.lambrecht@erasmusmc.nl
Hammad
Hamida
H
D000818:Animals; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D017951:Antigen Presentation; D016207:Cytokines / Q000378:metabolism; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance; D007113:Immunity, Innate; D008168:Lung / Q000187:drug effects / Q000276:immunology*; D008213:Lymphocyte Activation; D011971:Receptors, Immunologic / Q000378:metabolism; D012130:Respiratory Hypersensitivity / Q000188:drug therapy / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
D018926:Anti-Allergic Agents; D016207:Cytokines; D011971:Receptors, Immunologic